[go: up one dir, main page]

FR2868309B1 - Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression - Google Patents

Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression

Info

Publication number
FR2868309B1
FR2868309B1 FR0450653A FR0450653A FR2868309B1 FR 2868309 B1 FR2868309 B1 FR 2868309B1 FR 0450653 A FR0450653 A FR 0450653A FR 0450653 A FR0450653 A FR 0450653A FR 2868309 B1 FR2868309 B1 FR 2868309B1
Authority
FR
France
Prior art keywords
combatting
hmg
coa
preventing
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0450653A
Other languages
English (en)
Other versions
FR2868309A1 (fr
Inventor
Dominique Fagot
Pascal Portes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR0450653A priority Critical patent/FR2868309B1/fr
Publication of FR2868309A1 publication Critical patent/FR2868309A1/fr
Application granted granted Critical
Publication of FR2868309B1 publication Critical patent/FR2868309B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
FR0450653A 2004-04-02 2004-04-02 Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression Expired - Lifetime FR2868309B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0450653A FR2868309B1 (fr) 2004-04-02 2004-04-02 Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0450653A FR2868309B1 (fr) 2004-04-02 2004-04-02 Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression

Publications (2)

Publication Number Publication Date
FR2868309A1 FR2868309A1 (fr) 2005-10-07
FR2868309B1 true FR2868309B1 (fr) 2006-05-26

Family

ID=34944360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0450653A Expired - Lifetime FR2868309B1 (fr) 2004-04-02 2004-04-02 Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression

Country Status (1)

Country Link
FR (1) FR2868309B1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940292B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Peptides derives d'hmg-coa reductase et composition cosmetique et/ou pharmaceutique les contenant
FR2940291B1 (fr) * 2008-12-23 2012-12-21 Isp Investments Inc Peptide derive d'hmg-coa reductase et composition cosmetique ou pharmaceutique le contenant
FR2940125B1 (fr) * 2008-12-23 2013-03-22 Isp Investments Inc Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase
FR2940126B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase
US8933036B2 (en) 2009-04-15 2015-01-13 Isp Investments Inc. Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair
FR2944526B1 (fr) 2009-04-15 2013-05-10 Isp Investments Inc Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barriere
FR2944445B1 (fr) 2009-04-15 2013-08-16 Isp Investments Inc Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique apaisant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5902805A (en) * 1996-04-22 1999-05-11 L'oreal Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same
FR2798590B1 (fr) * 1999-09-21 2001-11-30 Oreal Utilisation de l'alverine pour diminuer les rides
FR2799649B1 (fr) * 1999-10-13 2005-05-20 Oreal Composition, notamment cosmetique, renfermant la dhea et un agent desquamant
FR2801508B1 (fr) * 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
FR2809005B1 (fr) * 2000-05-18 2002-12-27 Oreal Utilisation du manganese dans le traitement des rides
FR2838344B1 (fr) * 2002-04-12 2005-06-17 Oreal Utilisation d'une sapogenine, ou d'un extrait naturel contenant, pour lisser les rides et ridules d'expression

Also Published As

Publication number Publication date
FR2868309A1 (fr) 2005-10-07

Similar Documents

Publication Publication Date Title
EP1827436A4 (fr) Inhibiteurs d'activite akt
ZA200501913B (en) New compounds for the inhibition of rotamases and use thereof
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
EP1734965A4 (fr) Compositions et methodes permettant d'assurer l'hygiene de la paupiere
HK1089167A1 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use 2-
EP1606285A4 (fr) Inhibiteurs de ido et procedes d'utilisation de ceux-ci
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP1507541A4 (fr) Inhibiteurs et procedes d'utilisation de ceux-ci
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
HK1065259A1 (en) Water-in-oil emulsion cosmetic composition
DE602005018825D1 (de) Verpackung für rauchwaren und dergleichen
DE60334292D1 (de) Ylenverbundemulsionszusammensetzung und verwendung davon
EP1863769A4 (fr) Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
EP1735456A4 (fr) Compositions poylmeres et procedes associes d'utilisation
DE50305992D1 (de) Gassack für eine insassenschutzeinrichtung
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
FR2868309B1 (fr) Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression
PL371217A1 (en) Inhibitors of integrin alphavbeta6
PL1762219T3 (pl) Fotoochronne i/lub fotoimmunoochronne kompozycje do skóry i ich zastosowania
AU2003259076A1 (en) Absorbent product moisturizing and lubricating composition
EP1506778A4 (fr) Inhibiteurs de l'expression du tgf-$g(a)
AU2003211520A1 (en) Lfa-1 inhibitors and use thereof
FR2899469B1 (fr) Utilisation de derive de d- et l-fucose comme agent protecteur et/ou activateur des lymphocytes gamma delta t